1. Home
  2. MDAIW vs MSFT Comparison

MDAIW vs MSFT Comparison

Compare MDAIW & MSFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDAIW
  • MSFT
  • Stock Information
  • Founded
  • MDAIW N/A
  • MSFT 1975
  • Country
  • MDAIW United States
  • MSFT United States
  • Employees
  • MDAIW 78
  • MSFT N/A
  • Industry
  • MDAIW Medical/Dental Instruments
  • MSFT Computer Software: Prepackaged Software
  • Sector
  • MDAIW Health Care
  • MSFT Technology
  • Exchange
  • MDAIW Nasdaq
  • MSFT Nasdaq
  • Market Cap
  • MDAIW N/A
  • MSFT N/A
  • IPO Year
  • MDAIW 2021
  • MSFT 1986
  • Fundamental
  • Price
  • MDAIW $0.48
  • MSFT $446.20
  • Analyst Decision
  • MDAIW
  • MSFT Strong Buy
  • Analyst Count
  • MDAIW 0
  • MSFT 30
  • Target Price
  • MDAIW N/A
  • MSFT $512.07
  • AVG Volume (30 Days)
  • MDAIW N/A
  • MSFT 19.4M
  • Earning Date
  • MDAIW N/A
  • MSFT 01-29-2025
  • Dividend Yield
  • MDAIW N/A
  • MSFT 0.74%
  • EPS Growth
  • MDAIW N/A
  • MSFT 17.35
  • EPS
  • MDAIW N/A
  • MSFT 12.11
  • Revenue
  • MDAIW N/A
  • MSFT $254,190,000,000.00
  • Revenue This Year
  • MDAIW N/A
  • MSFT $15.84
  • Revenue Next Year
  • MDAIW N/A
  • MSFT $14.24
  • P/E Ratio
  • MDAIW N/A
  • MSFT $36.85
  • Revenue Growth
  • MDAIW N/A
  • MSFT 16.44
  • 52 Week Low
  • MDAIW N/A
  • MSFT $385.58
  • 52 Week High
  • MDAIW N/A
  • MSFT $468.35
  • Technical
  • Relative Strength Index (RSI)
  • MDAIW N/A
  • MSFT 63.63
  • Support Level
  • MDAIW N/A
  • MSFT $425.60
  • Resistance Level
  • MDAIW N/A
  • MSFT $434.48
  • Average True Range (ATR)
  • MDAIW 0.00
  • MSFT 7.76
  • MACD
  • MDAIW 0.00
  • MSFT 1.67
  • Stochastic Oscillator
  • MDAIW 0.00
  • MSFT 97.07

About MDAIW Spectral AI Inc.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Share on Social Networks: